July 30, 2010
 PDF Format |
Pacgen Reports Fiscal 2010 Financial Results |
June 8, 2010
PDF Format |
Pacgen Completes Share Consolidation |
May 28, 2010
PDF Format |
Pacgen Closes Private Placement Financing |
April 19, 2010
PDF Format |
Pacgen Announces Private Placement Financing and Financial Restructuring |
March 2, 2010
PDF Format |
Pacgen Reports Third Quarter Financial Results |
January 27, 2010
PDF Format |
Pacgen Signs Research Collaboration Agreements |
November 30, 2009
PDF Format |
Pacgen Reports Second Quarter Financial Results |
September 1, 2009
PDF Format |
Pacgen Reports First Quarter Financial Results |
August 13, 2009
PDF Format |
Pacgen Completes Acquisition of Xphase Pharmaceuticals |
July 31, 2009
PDF Format |
Pacgen Reports Fiscal 2009 Financial Results |
June 8, 2009
PDF Format |
Pacgen Signs Share Purchase Agreement to Acquire Xphase Pharmaceuticals |
April 28, 2009
PDF Format |
Pacgen to Acquire Xphase Pharmaceuticals |
April 14, 2009
PDF Format |
Pacgen Appoints New Director |
March 30, 2009
PDF Format |
Pacgen Announces Second Closing of Private Placement Financing |
March 3, 2009
PDF Format |
Pacgen Reports Third Quarter Financial Results |
February 3, 2009
PDF Format |
Pacgen Announces First Closing of Private Placement Financing |
January 30, 2009
PDF Format |
Pacgen Announces Private Placement Financing |
January 12, 2009
PDF Format |
Pacgen Announces Board Changes |
December 29, 2008
PDF Format |
Pacgen Terminates Letter of Intent with Medigen |
December 1, 2008
PDF Format |
Pacgen Reports Second Quarter Financial Results |
October 31, 2008
PDF Format |
Pacgen Appoints Interim Chief Executive Officer |
October 24, 2008
PDF Format |
Pacgen Enters Into a Letter of Intent with Medigen |
August 29, 2008
PDF Format |
Pacgen Reports First Quarter Financial Results |
July 29, 2008
PDF Format |
Pacgen Reports Fiscal 2008 Financial Results |
June 5, 2008
PDF Format |
Pacgen Announces Positive Results from Phase IIb Dose-Ranging Trial of PAC-113 |
April 15, 2008
PDF Format |
Pacgen Completes Patient Recruitment for Phase II Dose Ranging Trial of Novel Anti-Fungal Drug |
March 17, 2008
PDF Format |
Pacgen Closes $903,000 Private Placement Financing |
February 29, 2008
PDF Format |
Pacgen Reports Third Quarter Financial Results |
November 28, 2007
PDF Format |
Pacgen Reports Second Quarter Financial Results |
November 19, 2007
PDF Format |
Pacgen Initiates a Phase IIB Clinical Trial for PAC-113 |
November 13, 2007
PDF Format |
Pacgen Presents Research Data at ACCP on Evaluation of a New Host Derived Synthetic Antifungal Peptide (PAC-113) in the Treatment of Oral Candidiasis |
November 1, 2007
PDF Format |
Pacgen to Present at the 9th Annual Acumen BioFin Rodman & Renshaw Healthcare Conference |
October 10, 2007
PDF Format |
Pacgen to Present at BIO InvestorForum 2007 |
October 3, 2007
PDF Format |
Pacgen to Present at BioContact Quebec 2007 |
September 24, 2007
PDF Format |
Pacgen Announces Advances in PAC-113 Program |
August 28, 2007
PDF Format |
Pacgen Reports Fiscal 2008 First Quarter Results |
July 30, 2007
PDF Format |
Pacgen Reports Fiscal 2007 Fourth Quarter Results |
May 7, 2007
PDF Format |
Pacgen Announces Positive Results from Phase I/II Trial of Novel Anti-Fungal Drug
 listen to the Webcast |
April 17, 2007
PDF Format |
Pacgen
to Present at BioFinance 2007 |
March 30, 2007
PDF Format |
Pacgen
Builds on New Leadership and Updates Options Outstanding |
March 15, 2007
PDF Format |
Pacgen Completes Patient Recruitment for Phase I/II Trial of Novel Anti-Fungal Drug |
March 13, 2007
PDF Format |
Pacgen Appoints Robert DuFresne as President & CEO
listen
to the Webcast |
March 1, 2007
PDF Format |
Pacgen Reports Third Quarter Financial and Operating Results |
February 12, 2007
PDF Format |
Pacgen Appoints New Scientific Advisory Board Members |
December 7, 2006
PDF Format |
Pacgen Announces Closing of its Initial Public Offering |
August 30, 2006
PDF Format |
Pacgen Biopharmaceuticals Files for Initial Public Offering |
July 17, 2006
PDF Format |
Pacgen Biopharmaceuticals Names Dr. Alan Moore and Mr. Kevin McGarry to the Board of Directors |
April 20, 2006
PDF Format |
Pacgen
Biopharmaceuticals Appoints Christina Yip as Chief Financial
Officer |
April 12, 2006
PDF Format |
Pacgen
Biopharmaceuticals Acquires IL Therapeutics Inc. |
March 7, 2006
PDF Format |
Pacgen
Biopharmaceuticals Receives Approval for Phase I/II Clinical
Trial of PAC-113 for Oral Candidiasis |
October 24, 2005
PDF Format |
Pacgen
Biopharmaceuticals Contracts Vancouver-based Syreon Corporation
for its Phase I/II Clinical Trials of PAC-113 Mouthrinse
in HIV Seropositive Patients with Oral Candidiasis |
April 11, 2005
PDF Format |
Pacgen
Biopharmaceuticals Retains Dow Pharmaceutical Sciences
for PAC-113 Phase I/II Human Clinical Trials |
March 22, 2005
PDF Format |
Pacgen
Biopharmaceuticals In-Licenses Compounds for Oral Diseases
from Demegen
|
